Cadrenal Therapeutics

Cadrenal Therapeutics works on 1 rare disease tracked on Trial Friend, including Heparin-Induced Thrombocytopenia.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic (blood clotting) conditions.

The lead program, CAD-1005, is a first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT) — a deadly immune-mediated reaction where the body's response to heparin causes dangerous clots. Mortality from HIT can exceed 20% in some studies. If approved, CAD-1005 would be the first new HIT therapy in more than 2 decades.

On April 30, 2026, Cadrenal announced a successful End-of-Phase 2 meeting with the FDA and a clear Phase 3 path. Phase 2 data showed a more than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy. The planned Phase 3 trial is randomized, blinded, and placebo-controlled in approximately 120 patients across up to 50 sites worldwide, with a projected NDA submission in 2029. CAD-1005 holds FDA Orphan Drug and Fast Track designations and orphan drug status from the European Medicines Agency.

The broader pipeline includes tecarfarin, a late-stage oral blood thinner being developed for patients who need long-term anticoagulation (including those on dialysis or living with a left ventricular assist device), and frunexian, a parenteral Factor XIa inhibitor for use in acute hospital settings.